David Wyn Calvert Jones

Title: David Wyn Calvert Jones: Innovator in Chemical Compounds

Introduction

David Wyn Calvert Jones is a notable inventor based in Bristol, GB. He has made significant contributions to the field of chemical compounds, particularly in the development of innovative pharmaceutical solutions. His work has implications for the treatment of various health conditions.

Latest Patents

David Wyn Calvert Jones holds a patent for chemical compounds, specifically for two polymorphic forms of bis[(E)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl](3R,5S)-3,5-dihydroxyhept-6-enoic acid] calcium salt. This patent describes processes for making these compounds and their use as HMG Co-A reductase inhibitors. His innovative approach has the potential to enhance therapeutic options in the pharmaceutical industry.

Career Highlights

David is currently employed at AstraZeneca UK Limited, a leading global biopharmaceutical company. His role involves research and development in the field of chemical compounds, where he applies his expertise to create effective solutions for health challenges.

Collaborations

Throughout his career, David has collaborated with talented professionals, including Rebecca Jane Booth and Peter Anthony Cittern. These collaborations have fostered a productive environment for innovation and advancement in their respective fields.

Conclusion

David Wyn Calvert Jones exemplifies the spirit of innovation in the pharmaceutical industry through his groundbreaking work on chemical compounds. His contributions continue to influence the development of new treatments and improve patient outcomes.